Shares in AstraZeneca and Ionis Pharmaceuticals tumbled after reporting their Wainua drug failed to meet the primary target in a heart disease trial

3 days ago 8

The drugmakers said the cause didn’t conscionable its superior nonsubjective successful a Phase 3 proceedings erstwhile treating a uncommon benignant of bosom disease.

Read Entire Article

Shares in AstraZeneca and Ionis Pharmaceuticals tumbled after reporting their Wainua drug failed to meet the primary target in a heart disease trial

Related

Endometriosis groups 'crying out' for cut in diagnosis time

Why wellness is booming at festivals in the UK

We are living fewer years in good health: Is the NHS part of...

Popular

Clusters of Severe Stomach Illness Reported Across the U.S.

Heat waves are taking a big toll on chickens

New Strikes on Ships in Strait of Hormuz Test U.S.-Iran Ceas...

Platner’s Democratic Support Evaporates After Sexual Assault...

What really worries Reform about Posh George?